Discontinued — last reported Q2 '21
Unrecognized Tax Benefits - Impacting Effective Tax Rate
Vertex Pharmaceuticals Unrecognized Tax Benefits - Impacting Effective Tax Rate increased by 2.3% to $421.60M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 22.4%, from $344.50M to $421.60M. Over 4 years (FY 2020 to FY 2024), Unrecognized Tax Benefits - Impacting Effective Tax Rate shows an upward trend with a 45.7% CAGR.
Analysis
How to read this metric
An increase suggests higher tax uncertainty, while a decrease may indicate the resolution of tax audits or the expiration of statutes of limitations.
Detailed definition
This represents the portion of tax positions taken by the company that have not been recognized in the financial stateme...
Peer comparison
Highly dependent on the company's global tax footprint and audit environment; peers with similar international operations show comparable levels of tax uncertainty.
unrecognized_tax_benefits_impacting_etrHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $84.50M | $89.00M | $129.50M | $137.40M | $145.20M | $144.90M | $208.50M | $232.20M | $250.40M | $245.40M | $288.70M | $301.60M | $309.30M | $344.50M | $341.40M | $357.40M | $412.10M | $421.60M |
| QoQ Change | — | +5.3% | +45.5% | +6.1% | +5.7% | -0.2% | +43.9% | +11.4% | +7.8% | -2.0% | +17.6% | +4.5% | +2.6% | +11.4% | -0.9% | +4.7% | +15.3% | +2.3% |
| YoY Change | — | — | — | — | +71.8% | +62.8% | +61.0% | +69.0% | +72.5% | +69.4% | +38.5% | +29.9% | +23.5% | +40.4% | +18.3% | +18.5% | +33.2% | +22.4% |
Unrecognized Tax Benefits - Impacting Effective Tax Rate at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's unrecognized tax benefits - impacting effective tax rate?
- Vertex Pharmaceuticals (VRTX) reported unrecognized tax benefits - impacting effective tax rate of $421.60M in Q3 2025.
- How has Vertex Pharmaceuticals's unrecognized tax benefits - impacting effective tax rate changed year-over-year?
- Vertex Pharmaceuticals's unrecognized tax benefits - impacting effective tax rate increased by 22.4% year-over-year, from $344.50M to $421.60M.
- What is the long-term trend for Vertex Pharmaceuticals's unrecognized tax benefits - impacting effective tax rate?
- Over 4 years (2020 to 2024), Vertex Pharmaceuticals's unrecognized tax benefits - impacting effective tax rate has grown at a 45.7% compound annual growth rate (CAGR), from $75.80M to $341.40M.
- What does unrecognized tax benefits - impacting effective tax rate mean?
- Potential tax savings that are currently excluded from financial results due to uncertainty.